Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.58 |
| ▸ | FADS1 | O60427 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 6/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | LCK | P06239 | 2/20 | 0.56 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.55 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.55 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.55 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.55 |
| ▸ | CDK1 | P06493 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29110509 | 0.84 | EGFR (0.67) | EGFRERBB2FBP1 | |
| SCHEMBL13214883 | 0.83 | ABL1 (0.65) | EGFRMAPTKDM4EMEN1KMT2A | |
| SCHEMBL6219993 | 0.82 | EGFR (0.58) | EGFRERBB2ABL1BCRFBP1 | |
| SCHEMBL4414264 | 0.81 | MAPT (0.57) | EGFRFADS1MAPTKDM4EMEN1 | |
| SCHEMBL29110515 | 0.81 | EGFR (0.60) | EGFRMAPTHTTLMNATSHR | |
| SCHEMBL7022406 | 0.81 | EGFR (0.57) | EGFRMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL4052839 | 0.81 | KDM4E (0.75) | MAPTKDM4EMEN1KMT2AHTT | |
| Hydrochloric Acid SCHEMBL7017577 | 0.80 | EGFR (0.56) | EGFRMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL29771431 | 0.77 | MAPT (0.57) | EGFRFADS1MAPTKDM4EMEN1 | |
| SCHEMBL29110517 | 0.77 | MAPT (0.57) | EGFRFADS1MAPTKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008089310-A2 | DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF OBESITY | LEXICON PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | claimed |
| WO-2008089307-A2 | DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF PAIN, INFLAMMATION AND CANCER | LEXICON PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | claimed |
| US-20240216316-A1 | DIHOMO-GAMMA LINOLENIC ACID (DGLA) IS A NOVEL SENOLYTIC | BUCK INST RES AGING (US) | 2024-07-04 | — | — | US | disclosed |
| CN-114957262-B | Preparation method of C-6-position arylation deazapurine derivative | 浙江工业大学 | 2023-11-17 | — | — | CN | disclosed |
| CN-114848648-B | Application of C-6-position arylation deazapurine derivative in preparation of antitumor drugs | 浙江工业大学 | 2023-07-14 | — | — | CN | disclosed |
| CN-114957262-A | Preparation method of C-6-arylation deazapurine derivative | 浙江工业大学 | 2022-08-30 | — | — | CN | disclosed |
| CN-114848648-A | Application of C-6 arylation deazapurine derivative in preparation of antitumor drugs | 浙江工业大学 | 2022-08-05 | — | — | CN | disclosed |
| US-20080200458-A1 | Methods and compositions for the treatment of body composition disorders | LEXICON PHARMACEUTICALS, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080194557-A1 | Methods and compositions for the treatment of pain, inflammation and cancer | LEXICON PHARMACEUTICALS, INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2008089310-A2 | DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF OBESITY | LEXICON PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008089307-A2 | DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF PAIN, INFLAMMATION AND CANCER | LEXICON PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194557-A1 | Methods and compositions for the treatment of pain, inflammation and cancer | TNF, IL6, CXCL8 | EGFR 1259/4885FADS1 1059/4885MAPT 1069/4885 |
| US-20240216316-A1 | DIHOMO-GAMMA LINOLENIC ACID (DGLA) IS A NOVEL SENOLYTIC | DAGLA, DAGLB, MGLL | EGFR 2964/4885FADS1 192/4885MAPT 4494/4885 |
| US-20080200458-A1 | Methods and compositions for the treatment of body composition disorders | CPT1B, CPT1A, SHBG | EGFR 3860/4885FADS1 270/4885MAPT 2635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.